Company intelligence / Profile preview

Zeng Xi

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Zengxi Biotechnology is a biotechnology company headquartered in Shanghai, China, dedicated to the development of induced pluripotent stem cell (iPSC)-derived therapies for regenerative medicine. The company focuses on addressing cardiovascular diseases, particularly heart failure, by engineering functional cardiomyocytes to repair and replace damaged heart tissue. Zengxi's proprietary technology platform enables the efficient differentiation and large-scale production of high-purity cell products. By leveraging advanced stem cell biology, the company aims to provide innovative solutions for organ regeneration and improve outcomes for patients with chronic heart conditions.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyInduced pluripotent stem cell derived therapyStem cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Zeng Xi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zeng Xi.

Explore the full profile